U.S. recommends “pause” on single-dose Johnson & Johnson COVID-19 vaccine

The U.S. is suggesting a “pause” in administration of the single-dose Johnson and Johnson COVID-19 vaccine to explore reports of conceivably risky blood clots.

In a joint proclamation Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said it was examining clots in six women in the days after vaccination, in blend with decreased platelet checks. More than 6.8 million doses of the J&J vaccine have been managed in the U.S.

U.S. federal distribution channels, including mass vaccination locales, will pause the utilization of the J&J shot, and states and different suppliers are relied upon to follow.

CDC’s Advisory Committee on Immunization Practices will meet Wednesday to talk about the cases and the FDA has additionally dispatched an examination of the cases.

“Until that cycle is finished, we are suggesting a pause in the utilization of this vaccine out of a wealth of alert,” Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in a joint articulation.